HURN Huron Consulting Group Inc. Insider Trading

Director McCartney sells 6,500 HURN shares in 2 transactions at $161.15–$162.34 for $1.0M; retains 43.3K shares post-sale.

John McCartney, Director, executed two separate sales on 2025-11-19, selling 4,908 shares at $161.15 and 1,592 shares at $162.34 for a combined $1,049,369.48 at a blended average price of $161.44. This represents a -13.0% reduction in his holdings from 49.8K to 43.3K shares. The sales occurred near current price levels ($163.35 is only -3.7% from the 52-week high), and the timing follows a strong near-term rally (+7.2% over 30 days, +17.8% over 90 days). McCartney's cross-ticker track record shows 20 prior buys with a 90-day win rate of 20.00% and negative average returns (-2.9% avg 90d), suggesting limited predictive accuracy on his transaction timing overall. The company's fundamentals remain solid (P/E 25.97, 8.8% annual revenue growth, $30.4M net income), providing no obvious operational red flags that would explain the sale.

COO Dail James Ronald sold 7,991 shares at $169.56 avg price on 2025-10-29/30, reducing stake from 39.0K to 31.0K shares (-20.5%).

Dail James Ronald, Chief Operating Officer of Huron Consulting Group, executed 7 separate sales across two trading days totaling 7,991 shares for $1,354,979.27, reducing his shareholding by 20.5%. The sales occurred near the 52-week high of $169.61, with transaction prices ranging from $160.00 to $173.25 and a blended average of $169.56. The stock currently trades at $164.44, down 3.0% from its 52-week high, having gained 11.4% over the past 30 days and 34.8% over 90 days. The company shows solid fundamentals with $441.3M quarterly revenue, $30.4M net income, 8.8% annual revenue growth, and a 26.14 P/E ratio.

Director Roth James H sold 8,641 shares of HURN for $1,230,328.82 across 5 separate transactions on 2025-03-26 at prices ranging from $141.30 to $145.62.

James H Roth, a director at Huron Consulting, executed 5 separate sales totaling 8,641 shares for $1,230,328.82 on March 26, 2025, reducing his holdings by 15.4% to 47,638 shares post-transaction. The sales occurred at prices between $141.30 and $145.62, with a blended average of $142.38, while the current market price stands at $142.30, indicating the transactions executed near present market levels. Roth's cross-ticker historical track record shows 10 prior sells, but his same-ticker history at HURN reveals only recent activity (five prior trades in early-to-mid March, all sells, with outcomes not yet measurable at 90 days). Without additional context on whether this filing represents scheduled trading under a Rule 10b5-1 plan or discretionary open-market activity, this sale represents a material reduction in an individual director's exposure but lacks sufficient historical timing pattern evidence at this ticker to signal broader conviction shifts.

HURN director Roth sells 8,642 shares across 3 trades totaling $1,289,989.38; retains 56,279 shares post-sale

Director James H. Roth executed 3 separate open-market sales on 2025-03-19, totaling 8,642 shares for $1,289,989.38 at a blended average price of $149.27, reducing his holdings by 13.3% to 56,279 shares. The transaction occurred 7 days after a cluster of 4 sales on 2025-03-12 and represents a continuation of recent selling activity at the ticker. At the current price of $140.87, the stock has retreated 7.6% from its 52-week high of $152.46, though it has appreciated 7.4% over the prior 30 days and 15.5% over 90 days. With HURN trading at a P/E of 17.83 and posting annual revenue growth of 8.8% on a $378.1M quarterly revenue base, the company maintains solid operational fundamentals; the disposal itself does not signal deterioration in the underlying business.

Director Roth James H sold 8,642 shares at $142.43–$145.34 on 2025-03-12 for $1,243,802.01

Director James H Roth executed four separate sales totaling 8,642 shares for $1,243,802.01 at prices ranging from $142.43 to $145.34 on 2025-03-12, reducing his holdings by -11.7% to 64,921 shares. The sales occurred as HURN traded near its 52-week high of $152.46 (current price of $147.76 is -3.1% below peak), and followed immediately after three prior sells by the same insider on 2025-03-05, suggesting a concentrated divestment pattern over consecutive trading days. With cross-ticker open-market history of only 3 prior sales and SAME-TICKER history showing his three prior trades on 2025-03-05 with outcomes not yet measurable, this filing provides limited predictive signal from his historical timing accuracy. The company's fundamentals remain solid (P/E of 18.70, annual revenue growth of +8.8%, net income of $27,149,000.00), and HURN's stock is up 22.5% over 90 days, offering no obvious fundamental distress signal corresponding to the divestment.

Director Roth sells 8,642 shares of HURN for $1,278,364.16 at $147.92 average (near 52-week high)

On 2025-03-05, James H Roth, a Director at Huron Consulting Group Inc., executed 3 separate sales totaling 8,642 shares for $1,278,364.16. The blended average sale price of $147.92 places the transactions at the upper end of the 52-week range ($85.22–$152.46), approximately -2.1% from the 52-week high. Post-transaction holdings of 73,563 shares represent a -10.5% reduction from the prior 82,205 shares. The stock has appreciated +18.3% over the prior 30 days and +21.3% over 90 days, and HURN's fundamentals show stable growth with +8.8% annual revenue growth and a reasonable P/E of 18.90. The sale's proximity to recent price highs and elevated momentum warrants examination of the filer's prior trade patterns and any company-specific context.

CEO Mark Hussey sells 27,672 shares for $4,037,740.03 across 5 transactions on 2025-03-04

CEO and President Mark Hussey executed 5 separate sales totaling 27,672 shares for $4,037,740.03 on a single date, reducing his holdings by 25.4% from 108,790 to 81,118 shares. The blended average sale price of $145.91 sits just 0.24% above the current price of $145.46, with transactions executed across an 2.18-point price range ($144.63–$148.48). This is notable context: his prior three sales at HURN (on 2024-07-12) were followed by modest post-sale appreciation (90-day returns of 4.1%, 3.1%, and 4.9% respectively), indicating that his previous exit signals at this ticker were not well-timed by the downside. The current transaction occurs with HURN trading at 18.41 P/E and the stock up 18.2% over 90 days and +16.6% over 30 days—at the upper end of its 52-week range. An investor should monitor whether this large, multi-transaction reduction signals a change in the CEO's conviction at elevated valuations, or reflects routine portfolio management unrelated to business fundamentals.

Director Eugene Lockhart sold 12,500 shares of HURN at $150.00 for $1,875,000; post-transaction holdings reduced to 12,172 shares (-50.7%).

Director H. Eugene Lockhart sold 12,500 shares (-50.7% vs pre-transaction holdings) at $150.00 on 2025-02-26, reducing his direct stake from 24,672 shares to 12,172 shares. The transaction occurred near the stock's 52-week high of $152.46, with the company trading at a P/E of 19.30 and recent positive momentum (+19.2% over 30 days, +24.1% over 90 days). The sale represents a substantial reduction in his position, though he retains meaningful ownership. Investors should note the magnitude of this divested stake relative to his prior holdings and assess whether it reflects a broader pattern of insider activity at the company.

HURN CEO Mark Hussey sold 34,013 shares across 3 separate transactions totaling $3,424,637.40, reducing holdings to 85,081 shares (-28.6%)

CEO Mark Hussey executed 3 separate sales totaling 34,013 shares for $3,424,637.40 on 2024-07-12, reducing his shareholding by 28.6% from 119,094 to 85,081 shares. The sales occurred at blended average price of $100.69, 8 dollars below the current price of $108.75, suggesting the timing of this large reduction is not advantageous relative to prevailing market levels. While Huron's fundamentals remain solid—annual revenue growth of +20.7% and gross market cap of $1,958,129,662.50—the substantial and simultaneous reduction in CEO stake merits investor attention regarding underlying confidence levels or strategic intent behind the liquidation.